

DISCLOSURES ON EMPLOYEE STOCK OPTION SCHEME FOR THE YEAR ENDED MARCH 31, 2024

(Pursuant to Rule 12 (9) of Company (Share Capital & Debenture) Rules 2014 & Regulation 14 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021)

Sl. No.	Particulars	Status of compliance
1.	The board of directors in their report shall disclose any material change in the scheme(s) and whether the scheme(s) is/ are in compliance with the regulations.	There are no material changes in the Scheme. Please refer Clause 5 (ii) of the Board's report. The Scheme is in compliance with the regulation.
2.	Further, the following details, inter alia, shall be disclosed on the company's website and a web- link thereto shall be provided in the report of board of directors.	
A.	Relevant disclosures in terms of the accounting standards prescribed by the Central Government in terms of Section 133 of the Companies Act, 2013 (18 of 2013) including the Guidance note on accounting for employee share-based payments issued in that regard from time to time.	The Company has established employee stock option plans for certain categories of employees of the Company. Please refer Notes to Financial Statements which form part of this Report.
B.	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	Diluted earnings per share: ₹15.50
C.	Details related to Employees Stock Option Scheme (ESOS)	
(i)	A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including -	
	(a) Date of shareholders' approval	Scheme 2020 September 23 2020
	(b) Total number of options approved under ESOS	2,92,306
	(c) Vesting requirements	For 24 employees: 1 st Vesting - 9% of individual grants without any criteria; 2 nd Vesting - On achievement of 2021-22 target turnover as per slab; For 3 employees: Single Vesting - On achievement of 2020-21 target turnover;
	(d) Exercise price or pricing formula	Grant Price is the closing market price of the equity shares of Amrutanjan Health Care Limited as on 30.09.2020 as per National Stock Exchange records. Exercise Price will be the Grant Price after allowing a discount of ₹70/- per Option.
	(e) Maximum term of options granted	3 years
	(f) Source of shares (primary, secondary or combination)	Secondary
	(g) Variation in terms of options	Options vary depending upon the cadre, criticality of the position, seniority etc.
(ii)	Method used to account for ESOS - Intrinsic or fair value.	Fair Value
(iii)	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	Not Applicable as fair value has been accounted
(iv)	Option movement during the year (for each ESOS):	
	Number of options outstanding at the beginning of the period	48,222
	Number of options granted during the year	-
	Number of options forfeited / lapsed during the year	6,586
	Number of options vested during the year	41,636
	Number of options exercised during the year	33,066
	Number of shares arising as a result of exercise of options	-
	Money realized by exercise of options (INR), if scheme is implemented directly by the company	-

SI. No.	Particulars	Status of compliance
	Loan repaid by the Trust during the year from exercise price received	₹140 (in Lakhs)
	Number of options outstanding at the end of the year	8,570
	Number of options exercisable at the end of the year	8,570
(v)	Weighted-average exercise prices and weighted-average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.	The weighted average exercise price of all the options granted during the year and outstanding at the year ended March 31, 2024 is ₹353 /-
(vi)	Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to -	
	(a) senior managerial personnel as defined under Regulation 16 (d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015	No options granted during the year 2023-24
	(b) any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year; and	No options granted during the year 2023-24
	(c) identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant.	No options granted during the year 2023-24
(vii)	A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:	Assumptions used in determination of the fair value of the stock options under the Black Scholes Model
	(a) i) the weighted-average values of share price,	353
	ii) exercise price,	353
	iii) expected volatility,	32.69%
	iv) expected option life,	1-3 years
	v) expected dividends,	0.28%
	vi) the risk-free interest rate and	6.18%
	vii) any other inputs to the model;	NIL
	(b) the method used and the assumptions made to incorporate the effects of expected early exercise;	The assumptions for the exercise period have been incorporated based on the vesting period based on management analysis.
	(c) how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and	Expected volatility is based on historical volatility of the market prices of the Company's publicly traded equity shares during the expected term of the option grant.
	(d) Whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition.	Same as above

Details of Trust

The following details, inter alia, in connection with transactions made by the Trust meant for the purpose of administering the Scheme 2020

General information on all schemes

SI. No.	Particulars	Details
1.	Name of the Trust	AMRUTANJAN HEALTH CARE LIMITED ESOP TRUST
2.	Details of the Trustee (s)	SURANA AND SURANA INTERNATIONAL ATTORNEYS
3.	Amount of loan disbursed by company / any company in the group, during the year	NIL
4.	Amount of loan outstanding (repayable to company / any company in the group) as at the end of the year	₹168.17 (in Lakhs)
5.	Amount of loan, if any, taken from any other source for which company / any company in the group has provided any security or guarantee	NIL
6.	Any other contribution made to the Trust during the year	NIL

Brief details of transactions in shares by the Trust

- (a) Number of shares held at the beginning of the year; 52,232
- (b) Number of shares acquired during the year through
 - (i) Primary issuance- NIL
 - (ii) Secondary acquisition, also as a percentage of paid up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share- NIL
- (c) Number of shares transferred to the employees / sold along with the purpose thereof-

Transferred	-	33,066
Sold	-	48
- (d) Number of shares held at the end of the year- 19,118
- (e) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
Held at the beginning of the year	0.18% (52,232 equity shares)
Acquired during the year	-
Sold during the year	0.00% (48 equity shares)
Transferred to the employees during the year	0.11% (33,066 equity shares)
Held at the end of the year	0.07 % (19,118 equity shares)